Cite
HARVARD Citation
Andtbacka, R. et al. (n.d.). Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704). Journal for immunotherapy of cancer. p. . [Online].